AU2001282267A1 - Benzimidazole derivatives, preparation and therapeutic use thereof - Google Patents

Benzimidazole derivatives, preparation and therapeutic use thereof

Info

Publication number
AU2001282267A1
AU2001282267A1 AU2001282267A AU8226701A AU2001282267A1 AU 2001282267 A1 AU2001282267 A1 AU 2001282267A1 AU 2001282267 A AU2001282267 A AU 2001282267A AU 8226701 A AU8226701 A AU 8226701A AU 2001282267 A1 AU2001282267 A1 AU 2001282267A1
Authority
AU
Australia
Prior art keywords
preparation
therapeutic use
benzimidazole derivatives
benzimidazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282267A
Inventor
Francis Barth
Daniel Bichon
Frank Bolkenius
Viviane Van Dorsselaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0010419A external-priority patent/FR2812878B1/en
Priority claimed from FR0014696A external-priority patent/FR2816619B1/en
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU2001282267A1 publication Critical patent/AU2001282267A1/en
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS Amend patent request/document other than specification (104) Assignors: SANOFI-SYNTHELABO
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
AU2001282267A 2000-08-08 2001-08-06 Benzimidazole derivatives, preparation and therapeutic use thereof Abandoned AU2001282267A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0010419 2000-08-08
FR0010419A FR2812878B1 (en) 2000-08-08 2000-08-08 BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR0014696A FR2816619B1 (en) 2000-11-15 2000-11-15 BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR0014696 2000-11-15
PCT/FR2001/002556 WO2002012239A1 (en) 2000-08-08 2001-08-06 Benzimidazole derivatives, preparation and therapeutic use thereof

Publications (1)

Publication Number Publication Date
AU2001282267A1 true AU2001282267A1 (en) 2002-02-18

Family

ID=26212570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282267A Abandoned AU2001282267A1 (en) 2000-08-08 2001-08-06 Benzimidazole derivatives, preparation and therapeutic use thereof

Country Status (28)

Country Link
US (2) US6794382B2 (en)
EP (1) EP1309594B1 (en)
JP (1) JP2004505975A (en)
KR (1) KR20030020450A (en)
CN (1) CN1446218A (en)
AR (1) AR030121A1 (en)
AT (1) ATE284886T1 (en)
AU (1) AU2001282267A1 (en)
BG (1) BG107460A (en)
BR (1) BR0113046A (en)
CA (1) CA2412368A1 (en)
CZ (1) CZ294493B6 (en)
DE (1) DE60107859T2 (en)
EA (1) EA005950B1 (en)
EE (1) EE200300048A (en)
ES (1) ES2233671T3 (en)
HK (1) HK1053118A1 (en)
HR (1) HRP20030081A2 (en)
HU (1) HUP0301514A2 (en)
IL (1) IL153708A0 (en)
IS (1) IS6661A (en)
MX (1) MXPA03000753A (en)
NO (1) NO20030596L (en)
PL (1) PL365080A1 (en)
PT (1) PT1309594E (en)
SK (1) SK1582003A3 (en)
WO (1) WO2002012239A1 (en)
YU (1) YU7203A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110661676A (en) * 2018-06-29 2020-01-07 电信科学技术研究院有限公司 Method for measuring bandwidth part, method for configuring bandwidth part, terminal and network equipment

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
AU2003240742A1 (en) * 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
WO2004108723A1 (en) * 2003-06-04 2004-12-16 Altana Pharma Ag 4,5-dihydro-imidazo[4,5,1-ii]quinolin-6-ones as parp inhibitors
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
HUE025996T2 (en) 2003-12-01 2016-05-30 Kudos Pharm Ltd DNA damage repair inhibitors for treatment of cancer
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CN101083986A (en) * 2004-09-20 2007-12-05 泽农医药公司 Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (scd)
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
BRPI0515482A (en) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc heterocyclic derivatives and their uses as therapeutic agents
AR051094A1 (en) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
AU2005286648A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003325A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors.
AR051090A1 (en) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
WO2006034446A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
DE602006018255D1 (en) * 2005-01-11 2010-12-30 Neurosearch As NEW 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CALCIUM-ACTIVATED CALIUM CHANNELS WITH LOW CONDUCTIVITY
JP2009513563A (en) * 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
BRPI0614168A2 (en) * 2005-08-05 2017-07-25 Astrazeneca Ab COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, ISOFORM, TAUTOMER, OPTICAL ISOMER OR A COMBINATION THEREOF, PHARMACEUTICAL COMPOSITION, METHOD FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSCHIATRIC DISORDERS, USE OF A COMPOUND, AND, PROCESS FOR THE PREPARATION OF A COMPOUND
JP2009541454A (en) * 2006-07-03 2009-11-26 ノイロサーチ アクティーゼルスカブ Combination of monoamine reuptake inhibitor and potassium channel activator
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
GB201220157D0 (en) * 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
CN103923088B (en) * 2013-01-11 2016-09-07 上海汇伦生命科技有限公司 2,5-diazabicyclo [2.2.1] heptane class compound and preparation method, its Pharmaceutical composition and in application pharmaceutically
EP3581576B1 (en) * 2013-03-15 2022-01-26 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor
CN104230896A (en) 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 Benzimidazole-2-piperazine heterocycle ramification and medicine composition as well as preparation method and application thereof
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CA2946731C (en) 2014-04-23 2022-06-07 Incyte Corporation 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
AU2016271762B2 (en) * 2015-05-29 2020-01-23 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity
CN109715625B (en) 2016-06-20 2022-04-19 因赛特公司 Crystalline solid forms of BET inhibitors
CN111349094B (en) * 2020-04-23 2021-02-02 杭州师范大学 6H-imidazo [4,5,1-ij ] quinolone and synthesis method and application thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710915B1 (en) * 1993-10-04 1995-11-24 Synthelabo Piperidine derivatives, their preparation and their therapeutic use.
FR2731708B1 (en) * 1995-03-13 1997-04-30 Synthelabo PIPERIDINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
UA61158C2 (en) * 1998-11-27 2003-11-17 Басф Акціенгезелльшафт Benzidimazole derivatives and a drug based thereon

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110661676A (en) * 2018-06-29 2020-01-07 电信科学技术研究院有限公司 Method for measuring bandwidth part, method for configuring bandwidth part, terminal and network equipment

Also Published As

Publication number Publication date
ATE284886T1 (en) 2005-01-15
NO20030596L (en) 2003-04-01
IL153708A0 (en) 2003-07-06
KR20030020450A (en) 2003-03-08
HK1053118A1 (en) 2003-10-10
CZ294493B6 (en) 2005-01-12
EP1309594B1 (en) 2004-12-15
AR030121A1 (en) 2003-08-13
BG107460A (en) 2003-09-30
DE60107859D1 (en) 2005-01-20
CZ2003354A3 (en) 2003-05-14
IS6661A (en) 2002-12-19
CA2412368A1 (en) 2002-02-14
NO20030596D0 (en) 2003-02-06
YU7203A (en) 2006-01-16
EA200201259A1 (en) 2003-06-26
US20050032779A1 (en) 2005-02-10
EA005950B1 (en) 2005-08-25
US20030203893A1 (en) 2003-10-30
HUP0301514A2 (en) 2003-09-29
CN1446218A (en) 2003-10-01
US6794382B2 (en) 2004-09-21
HRP20030081A2 (en) 2005-02-28
EE200300048A (en) 2004-12-15
JP2004505975A (en) 2004-02-26
WO2002012239A1 (en) 2002-02-14
PT1309594E (en) 2005-04-29
EP1309594A1 (en) 2003-05-14
ES2233671T3 (en) 2005-06-16
PL365080A1 (en) 2004-12-27
DE60107859T2 (en) 2005-12-22
MXPA03000753A (en) 2003-10-15
SK1582003A3 (en) 2003-08-05
BR0113046A (en) 2003-07-01

Similar Documents

Publication Publication Date Title
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU2002340999A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
IL159275A0 (en) Phenylsulfonyl-1, 3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
HK1048999A1 (en) Azepinoindole derivatives, their preparation and use thereof
AU3957600A (en) Piperidyl-imidazole derivatives, their preparations and therapeutic uses
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU2002359126A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2003255645A1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
AU2002359123A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
AU2003269018A1 (en) Acylaminothiazole derivatives, preparation and therapeutic use thereof
IL135451A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
AU3971500A (en) Indazole derivatives, preparation and therapeutic application thereof
HUP0201810A2 (en) Sootepenseone and its derivatives, their preparation and use as medicament
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
AU2002229870A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
PL365342A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
HUP0203468A3 (en) Betha-d-5-thioxylose derivatives, preparation method and therapeutic use thereof
AU2001237518A1 (en) Polyfluoroalkylimidazole derivatives, their preparation and therapeutic application
IL135452A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
HK1065792A1 (en) 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino Ä4,5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
AU3971800A (en) 2-alkoxy-cyclobutene-3,4-dione derivatives, preparation and therapeutic use thereof
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application